Dr Bagley on the ACTION Trial of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas

Stephen Bagley, MD, MSCE, discusses the phase 3 ACTION trial evaluating ONC201 in H3K27M-mutant diffuse midline gliomas.

Related Keywords

United States ,Stephen Bagley ,University Of Pennsylvania Hospital ,Pennsylvania Hospital ,Penn Medicine ,Phase 3 Action Trial ,Onc201 I ,H3k27m Mutant Diffuse Midline Gliomas ,Nct05580562 ,